panc02 03  (ATCC)

Journal: Oncology Letters

Article Title: Stimulator of interferon genes signaling network-driven prognostic signature for pancreatic cancer: Hub gene discovery with multimodal validation

doi: 10.3892/ol.2025.15348

Figure Lengend Snippet: Functional roles of IFIT2 and ZDHHC1 in PAAD oncobiology. (A) Human Protein Atlas representative immunohistochemical staining of six prognostic signature genes in PAAD tissues (proteinatlas.org). Scale bar, 100 µm. (B) Western blot and semi-quantification confirming successful ZDHHC1 overexpression in Panc02 cells (C) Western blot and semi-quantification confirming IFIT2 knockout efficiency in Panc02 cells (****P<0.0001). (D) CCK-8 assay: ZDHHC1 overexpression enhances Panc02 proliferation (***P<0.001 and ****P<0.0001 vs OE-NC). (E) CCK-8 assay: IFIT2 knockout enhances Panc02 proliferation (**P<0.01 and ***P<0.001 vs. sh-NC). (F) TUNEL assay (scale bar, 50 µm) demonstrating reduced apoptosis in ZDHHC1-overexpressing Panc02 cells. (G) TUNEL assay (scale bar 50 µm) showing decreased apoptosis in IFIT2-knockout Panc02 cells (**P<0.01). IFIT2, interferon-induced protein with tetratricopeptide repeats 2; ZDHHC1, zinc finger DHHC-type containing 1; PAAD, pancreatic ductal adenocarcinoma; OE, overexpression; CCK-8, Cell Counting Kit-8; DTX4, deltex E3 ubiquitin ligase 4; IFI16, interferon γ inducible protein 16; MAVS, mitochondrial antiviral-signaling protein; PRKDC, protein kinase DNA-activated catalytic subunit; sh-NC, scrambled negative control shRNA; ns, not significant.

Article Snippet: Panc02 cells (ATCC CRL-2553TM) were lysed in RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate and 0.1% SDS) supplemented with protease inhibitor cocktail (cat. no. 11836170001; Roche Diagnostics, GmbH).

Techniques: Functional Assay, Immunohistochemical staining, Staining, Western Blot, Over Expression, Knock-Out, CCK-8 Assay, TUNEL Assay, Cell Counting, Ubiquitin Proteomics, Negative Control, shRNA

Journal: Oncology Letters

Article Title: Stimulator of interferon genes signaling network-driven prognostic signature for pancreatic cancer: Hub gene discovery with multimodal validation

doi: 10.3892/ol.2025.15348

Figure Lengend Snippet: Functional roles of IFIT2 and ZDHHC1 in PAAD oncobiology. (A) Human Protein Atlas representative immunohistochemical staining of six prognostic signature genes in PAAD tissues (proteinatlas.org). Scale bar, 100 µm. (B) Western blot and semi-quantification confirming successful ZDHHC1 overexpression in Panc02 cells (C) Western blot and semi-quantification confirming IFIT2 knockout efficiency in Panc02 cells (****P<0.0001). (D) CCK-8 assay: ZDHHC1 overexpression enhances Panc02 proliferation (***P<0.001 and ****P<0.0001 vs OE-NC). (E) CCK-8 assay: IFIT2 knockout enhances Panc02 proliferation (**P<0.01 and ***P<0.001 vs. sh-NC). (F) TUNEL assay (scale bar, 50 µm) demonstrating reduced apoptosis in ZDHHC1-overexpressing Panc02 cells. (G) TUNEL assay (scale bar 50 µm) showing decreased apoptosis in IFIT2-knockout Panc02 cells (**P<0.01). IFIT2, interferon-induced protein with tetratricopeptide repeats 2; ZDHHC1, zinc finger DHHC-type containing 1; PAAD, pancreatic ductal adenocarcinoma; OE, overexpression; CCK-8, Cell Counting Kit-8; DTX4, deltex E3 ubiquitin ligase 4; IFI16, interferon γ inducible protein 16; MAVS, mitochondrial antiviral-signaling protein; PRKDC, protein kinase DNA-activated catalytic subunit; sh-NC, scrambled negative control shRNA; ns, not significant.

Article Snippet: 293T cells (ATCC ® CRL-3216TM) and murine pancreatic ductal adenocarcinoma Panc02 cells (cat. no. CRL-2553) were cultured in high-glucose DMEM medium (Corning, Inc.) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin (HyCloneTM; Cytiva).

Techniques: Functional Assay, Immunohistochemical staining, Staining, Western Blot, Over Expression, Knock-Out, CCK-8 Assay, TUNEL Assay, Cell Counting, Ubiquitin Proteomics, Negative Control, shRNA

Journal: Cell Reports Medicine

Article Title: ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy

doi: 10.1016/j.xcrm.2025.102336

Figure Lengend Snippet: STF-1623 controls Panc02 pancreatic tumor growth by activating anti-cancer immunity (A and B) BALB/c female mice with established subcutaneous Panc02 tumors received treatment indicated. On day 12 of the study, tumors were processed for flow cytometry: the percentage of IA-IE + CD206 low M1 macrophage (F4/80 + GR-1 − ) over IA-IE − CD206 high M2 macrophage, the number of CD335 + CD3 − NK cells, CD335 + CD3 + NKT cells, CD4 + CD3 + T cells, and CD8 + CD3 + T cells per gram of tumors, and the ratio of CD8 + T cells over Foxp3 + CD4 + Treg cells (A), CD69 + CD4 + T cells, PD-1 + CD4 + T cells, Ki67 + CD4 + T cells, CD69 + CD8 + T cells, PD-1 + CD8 + T cells, and Ki67 + CD8 + T cells (B). Mean ± SD is plotted, n = 6 mice for vehicle and STF-1623 groups, and n = 3 for all other combination therapy groups. (C) BALB/c female mice with established Panc02 tumors received the treatment as indicated. Mean ± SEM of tumor volume is plotted, n = 9–12 mice. Spider plots of individual tumor growth are shown. (D) Percent weight change of mice in (C) on day 45 compared to day 1 of the study. Mean ± SD is plotted, n = 9–12 mice. NK, natural killer; NKT, natural killer T; Treg, regulatory T cells; IR. ionizing radiation. p values were calculated by two-sided unpaired t test unless otherwise noted. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001; p value is shown if between 0.05 and 0.1.

Article Snippet: Mouse: Panc02 , ATCC , Cat# CRL-2553.

Techniques: Flow Cytometry